NAD+ IV Therapy for Energy and Brain Fog: An Honest Look

NAD+ IV Therapy for Energy and Brain Fog: An Honest Look

NAD+ IV drips are marketed for energy, focus, and mental clarity. Here’s what’s real, what’s still unproven, and how to think about it.

NAD+ infusions have become a fixture of the wellness world, promoted for everything from all-day energy to lifting brain fog. Some of the interest is grounded in genuine biology, and some runs ahead of the evidence. Here’s an honest breakdown.

What NAD+ is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell in your body. It’s essential for turning food into usable energy, repairing DNA, and running the cellular maintenance that keeps tissues — including the brain — working well. NAD+ levels tend to decline with age and stress, which is the core reason it’s become a target for supporting energy and resilience.

What the research supports

Two things are reasonably well established in humans. First, NAD+ precursors reliably raise NAD+ levels: randomized trials show that oral precursors like NMN and NR increase circulating NAD+. Second, in those trials the precursors were generally safe and well tolerated. Raising NAD+ is achievable and appears low-risk at studied doses.

A caveat that matters for IV specifically

Here’s an honest nuance that’s easy to miss: most of that solid trial evidence involves oral precursors, not intravenous NAD+ itself. Direct data on IV NAD+ is limited. In one pharmacokinetic pilot, IV NAD+ didn’t measurably raise blood NAD+ until about 24 hours after the infusion — and even then only modestly (on the order of a couple of percent). IV NAD+ is widely offered and many people report feeling better afterward, but the route-specific science is still thin. It’s reasonable to be curious about it; it’s also reasonable to keep expectations grounded.

What it doesn’t yet prove

Here’s the honest part: raising NAD+ is not the same as proving a specific benefit for energy, focus, or mood. Rigorous human trials tying NAD+ to those outcomes are limited, and some studies of functional endpoints have come back mixed or null. Many people do report feeling more energized and clear-headed, and those experiences are worth taking seriously — while holding them alongside the current limits of the data.

A note on safety and sourcing

The regulatory landscape here is shifting — as of 2025, the FDA has treated NMN as an investigational drug rather than a supplement, and quality and purity vary widely in this space. IV therapy also carries the ordinary considerations of any infusion. This is why clinical oversight and reputable sourcing matter, rather than DIY approaches.

The bottom line

NAD+ is real, important cellular biology, and raising it appears safe — but the benefits for energy and mental clarity are still being studied. Approached honestly and under clinical guidance, an NAD+ protocol may be a reasonable part of a broader wellness plan, with realistic expectations rather than hype.

Want an honest, personalized assessment — no hype? Refound Center offers clinician-guided consultations in the North Denver to Fort Collins area. Reach out and we’ll help you decide what actually makes sense for your goals.

Medical disclaimer

This article is for general educational purposes only and is not medical advice, diagnosis, or treatment. NAD+ and peptide therapies are not a substitute for evidence-based mental health care, and regulatory status for some compounds is evolving. Talk with a qualified clinician before starting any therapy. If you are in crisis or thinking about harming yourself, call or text 988 (the Suicide & Crisis Lifeline) in the U.S.

Sources & further reading (studies identified via PubMed):

Yi L, et al. Efficacy and safety of NMN supplementation in healthy middle-aged adults: a randomized controlled trial. GeroScience, 2022. https://doi.org/10.1007/s11357-022-00705-1

Christen S, et al. The differential impact of three NAD+ boosters on circulatory NAD+ in humans. Nature Metabolism, 2026. https://doi.org/10.1038/s42255-025-01421-8

Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/

Prokopidis K, et al. Effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle, 2025. https://doi.org/10.1002/jcsm.13799

U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks